Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease

Nature Reviews Drug Discovery

Volumn 8, Issue 2, 2009, Pages 139-152

  Fraisl, Peter ^a   Aragonés, Julián ^a   Carmeliet, Peter ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

8 QUINOLINOL DERIVATIVE; ADENOSINE; CICLOPIROXOLAMINE; DEFEROXAMINE; DIMETHYLOXALYLGLYCINE; ERYTHROPOIETIN; ETHYL 3,4 DIMETHYLBENZOIC ACID; FG 0041; FG 2229; FG 4497; FM 6008; GLUCOSE TRANSPORTER 1; GLYCINE DERIVATIVE; HYDRALAZINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MIMOSINE; N OXALYL DEXTRO PHENYLALANINE; NITRIC OXIDE SYNTHASE; OXIDOREDUCTASE INHIBITOR; OXYGEN; OXYGENASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE INHIBITOR; PROTEIN BNIP3; PROTEIN KINASE B; PYRIDINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TM 6008; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ANGIOGENESIS; AUTOPHAGY; BRAIN ISCHEMIA; CELL DEATH; CELL FUNCTION; CELL HYPOXIA; CELL SURVIVAL; DRUG DESIGN; DRUG TARGETING; ENZYME INHIBITION; HUMAN; INFLAMMATION; INHIBITION KINETICS; ISCHEMIA; ISCHEMIC HEART DISEASE; ISCHEMIC PRECONDITIONING; KIDNEY FAILURE; MOLE RAT; MORTALITY; MYOCARDIAL HIBERNATION; NONHUMAN; OXYGEN CONSUMPTION; OXYGEN SENSING; OXYGEN SUPPLY; PRIORITY JOURNAL; REVIEW; SEAL; STROKE; SURVIVAL RATE;

AMINO ACIDS, DICARBOXYLIC; ANGIOGENESIS INDUCING AGENTS; ANIMALS; ANOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; ISCHEMIA; ISCHEMIC PRECONDITIONING; MYOCARDIAL CONTRACTION; OXYGEN CONSUMPTION; PROCOLLAGEN-PROLINE DIOXYGENASE;

EID: 59349098621     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2761     Document Type: Review

References (195)

1. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
2. 2 tension. Proc. Natl Acad. Sci. USA 92, 5510-5514 (1995).
3. Kaelin, W. G., Jr & Ratcliffe, P. J. Oxygen sensing by metazoans: The central role of the HIF hydroxylase pathway. Mol. Cell 30, 393-402 (2008).
4. Bruick, R. K. & McKnight, S. L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 294, 1337-1340 (2001).
5. Epstein, A. C. et al. C. elegans EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 43-54 (2001).
6. Lando, D. et al. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 16, 1466-1471 (2002).
7. Mahon, P. C., Hirota, K. & Semenza, G. L. FIH-1: A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1 transcriptional activity. Genes Dev. 15, 2675-2686 (2001).
8. Ehrismann, D. et al. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem. J. 401, 227-234 (2007).
9. Koivunen, P., Hirsila, M., Gunzler, V., Kivirikko, K. I. & Myllyharju, J. Catalytic properties of the asparaginyl hydroxylase (FIH) in the oxygen sensing pathway are distinct from those of its prolyl 4-hydroxylases. J. Biol. Chem. 279, 9899-9904 (2004).
10. Gnaiger, E., Lassnig, B., Kuznetsov, A., Rieger, G. & Margreiter, R. Mitochondrial oxygen affinity, respiratory flux control and excess capacity of cytochrome c oxidase. J. Exp. Biol. 201, 1129-1139 (1998).
11. Ward, J. P. Oxygen sensors in context. Biochim. Biophys. Acta 1777, 1-14 (2008).
12. 2-regulated prolyl hydroxylation. Science 292, 468-472 (2001).
13. 2 sensing. Science 292, 464-468 (2001).
14. Stolze, I. P. et al. Genetic analysis of the role of the asparaginyl hydroxylase factor inhibiting hypoxia-inducible factor (HIF) in regulating HIF transcriptional target genes. J. Biol. Chem. 279, 42719-42725 (2004).
15. Ramirez, J. M., Folkow, L. P. & Blix, A. S. Hypoxia tolerance in mammals and birds: From the wilderness to the clinic. Annu. Rev. Physiol. 69, 113-143 (2007).
16. Kelly, D. P. Hypoxic reprogramming. Nature Genet. 40, 132-134 (2008).
17. Schmitz, A. & Harrison, J. F. Hypoxic tolerance in air-breathing invertebrates. Respir. Physiol. Neurobiol. 141, 229-242 (2004).
18. Aragones, J. et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nature Genet. 40, 170-180 (2008).
19. Eckle, T., Kohler, D., Lehmann, R., El Kasmi, K. & Eltzschig, H. K. Hypoxia-inducible factor-1 is central to cardioprotection: A new paradigm for ischemic preconditioning. Circulation 118, 166-175 (2008).
20. Simons, M. Angiogenesis: Where do we stand now? Circulation 111 1556-1566 (2005).
21. Carmeliet, P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 6, 389-395 (2000).
22. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nature Rev. Cancer 2, 38-47 (2002).
23. Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med. 9, 677-684 (2003).
24. Shyu, K. G. et al. Intramyocardial injection of naked DNA encoding HIF-1α/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat. Cardiovasc. Res. 54, 576-583 (2002).
25. Vincent, K. A. et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1α/VP16 hybrid transcription factor. Circulation 102, 2255-2261 (2000).
26. Kido, M. et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J. Am. Coll. Cardiol. 46 2116-2124 (2005).
27. Takeda, K., Cowan, A. & Fong, G. H. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 116, 774-781 (2007).
28. Minamishima, Y. A. et al. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood 111, 3236-3244 (2008).
29. Takeda, K. & Fong, G. H. Prolyl hydroxylase domain 2 protein suppresses hypoxia-induced endothelial cell proliferation. Hypertension 49 178-184 (2007).
30. Knowles, H. J., Tian, Y. M., Mole, D. R. & Harris, A. L. Novel mechanism of action for hydralazine: Induction of hypoxia-inducible factor-1α vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ. Res. 95, 162-169 (2004).
31. Milkiewicz, M., Pugh, C. W. & Egginton, S. Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice. J. Physiol. 560, 21-26 (2004).
32. Campbell, W. B., Graham, R. M., Jackson, E. K., Loisel, D. P. & Pettinger, W. A. Effect of indomethacin on hydralazine.induced renin and catecholamine release in the conscious rabbit. Br. J. Pharmacol. 71, 529-531 (1980).
33. Amaral, S. L., Roman, R. J. & Greene, A. S. Renin gene transfer restores angiogenesis and vascular endothelial growth factor expression in Dahl S rats. Hypertension 37, 386-390 (2001).
34. Freret, T. et al. Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur. J. Neurosci. 23, 1757-1765 (2006).
35. Siddiq, A. et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J. Biol. Chem. 280, 41732-41743 (2005).
36. Hayashi, T., Abe, K. & Itoyama, Y. Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J. Cereb. Blood Flow Metab. 18, 887-895 (1998).
37. Manoonkitiwongsa, P. S., Schultz, R. L., McCreery, D. B., Whitter, E. F. & Lyden, P. D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. J. Cereb. Blood Flow Metab. 24, 693-702 (2004).
38. Shen, F. et al. Adeno.associated viral-vector-mediated hypoxia-inducible vascular endothelial growth factor gene expression attenuates ischemic brain injury after focal cerebral ischemia in mice. Stroke 37, 2601-2606 (2006).
39. Gatenby, R. A. & Gillies, R. J. Why do cancers have high aerobic glycolysis? Nature Rev. Cancer 4, 891-899 (2004).
40. Comerford, K. M. et al. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 62, 3387-3394 (2002).
41. Zhang, H. et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 11, 407-420 (2007).
42. Zhang, H. et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J. Biol. Chem. 283, 10892-10903 (2008).
43. Dahia, P. L. et al. A HIF1α regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas. PLoS Genet. 1, 72-80 (2005).
44. Fukuda, R. et al. HIF1α regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell 129 111-122 (2007).
45. Kim, J. W., Tchernyshyov, I., Semenza, G. L. & Dang, C. V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell. Metab. 3, 177-185 (2006).
46. Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L. & Denko, N. C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell. Metab. 3, 187-197 (2006).
47. Liu, L. et al. Hypoxia-induced energy stress regulates mRNA translation and cell growth. Mol. Cell 21, 521-531 (2006).
48. Brugarolas, J. et al. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18, 2893-2904 (2004).
49. DeYoung, M. P., Horak, P., Sofer, A., Sgroi, D. & Ellisen, L. W. Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 22, 239-251 (2008).
50. -/- mice. Nature Genet. 35, 331-340 (2003).
51. Carey, H. V., Andrews, M. T. & Martin, S. L. Mammalian hibernation: cellular and molecular responses to depressed metabolism and low temperature. Physiol. Rev. 83, 1153-1181 (2003).
52. Andrews, M. T. Genes controlling the metabolic switch in hibernating mammals. Biochem. Soc. Trans. 32, 1021-1024 (2004).
53. Andrews, M. T., Squire, T. L., Bowen, C. M. & Rollins, M. B. Low-temperature carbon utilization is regulated by novel gene activity in the heart of a hibernating mammal. Proc. Natl Acad. Sci. USA 95, 8392-8397 (1998).
54. Buck, M. J., Squire, T. L. & Andrews, M. T. Coordinate expression of the PDK4 gene: A means of regulating fuel selection in a hibernating mammal. Physiol. Genomics 8, 5-13 (2002).
55. Galster, W. A. & Morrison, P. Seasonal changes in serum lipids and proteins in the 13-lined ground squirrel. Comp. Biochem. Physiol. 18, 489-501 (1966).
56. Harlow, H. J. & Frank, C. L. The role of dietary fatty acids in the evolution of spontaneous and facultative hibernation patterns in prairie dogs. J. Comp. Physiol. [B] 171, 77-84 (2001).
57. Drew, K. L. et al. Hypoxia tolerance in mammalian heterotherms. J. Exp. Biol. 207, 3155-3162 (2004).
58. Zhou, F. et al. Hibernation, a model of neuroprotection. Am. J. Pathol. 158, 2145-2151 (2001).
59. Bernhardt, W. M. et al. Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure. J. Am. Soc. Nephrol. 17, 1970-1978 (2006).
60. Hill, P. et al. Inhibition of hypoxia inducible factor hydroxylases protects against renal ischemia-reperfusion injury. J. Am. Soc. Nephrol. 19, 39-46 (2008).
61. Zhong, Z. et al. Activation of the oxygen-sensing signal cascade prevents mitochondrial injury after mouse liver ischemia-reperfusion. Am. J. Physiol. Gastrointest. Liver Physiol. 295, G823-G832 (2008).
62. Taylor, C. T. & Pouyssegur, J. Oxygen, hypoxia, and stress. Ann. NY Acad. Sci. 1113, 87-94 (2007).
63. Kulkarni, A. C., Kuppusamy, P. & Parinandi, N. Oxygen, the lead actor in the pathophysiologic drama: Enactment of the trinity of normoxia, hypoxia, and hyperoxia in disease and therapy. Antioxid. Redox Signal. 9, 1717-1730 (2007).
64. Bonnet, S. et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11, 37-51 (2007).
65. Heusch, G., Schulz, R. & Rahimtoola, S. H. Myocardial hibernation: A delicate balance. Am. J. Physiol. Heart Circ. Physiol. 288, H984-H999 (2005).
66. Fallavollita, J. A., Malm, B. J. & Canty, J. M. Jr. Hibernating myocardium retains metabolic and contractile reserve despite regional reductions in flow, function, and oxygen consumption at rest. Circ. Res. 92, 48-55 (2003).
67. Page, B. et al. Persistent regional downregulation in mitochondrial enzymes and upregulation of stress proteins in swine with chronic hibernating myocardium. Circ. Res. 102, 103-112 (2008).
68. Depre, C. et al. Program of cell survival underlying human and experimental hibernating myocardium. Circ. Res. 95, 433-440 (2004).
69. Kim, S. J. et al. Persistent stunning induces myocardial hibernation and protection: Flow/function and metabolic mechanisms. Circ. Res. 92, 1233-1239 (2003).
70. Hosokawa, R. et al. Myocardial metabolism of 1231-BMIPP during low-flow ischaemia in an experimental model: Comparison with myocardial blood flow and 18F-FDG. Eur. J. Nucl. Med. 28, 1630-1639 (2001).
71. Shimonagata, T. et al. Metabolic changes in hibernating myocardium after percutaneous transluminal coronary angioplasty and the relation between recovery in left ventricular function and free fatty acid metabolism. Am. J. Cardiol. 82, 559-563 (1998).
72. Heusch, G. Hibernating myocardium. Physiol. Rev. 78, 1055-1085 (1998).
73. Sridharan, V. et al. The prolyl hydroxylase oxygen-sensing pathway is cytoprotective and allows maintenance of mitochondrial membrane potential during metabolic inhibition. Am. J. Physiol. Cell Physiol. 292, C719-C728 (2007).
74. Ockaili, R. et al. HIF-1 activation attenuates postischemic myocardial injury: Role for heme oxygenase-1 in modulating microvascular chemokine generation. Am. J. Physiol. Heart Circ. Physiol. 289 H542-H548 (2005).
75. Wright, G., Higgin, J. J., Raines, R. T., Steenbergen, C. & Murphy, E. Activation of the prolyl hydroxylase oxygen-sensor results in induction of GLUT1, heme oxygenase-1, and nitric-oxide synthase proteins and confers protection from metabolic inhibition to cardiomyocytes. J. Biol. Chem. 278, 20235-20239 (2003).
76. May, D. et al. Transgenic system for conditional induction and rescue of chronic myocardial hibernation provides insights into genomic programs of hibernation. Proc. Natl Acad. Sci. USA 105, 282-287 (2008).
77. Nakai, A. et al. The role of autophagy in cardiomyocytes in the basal state and in response to hemodynamic stress. Nature Med. 13, 619-624 (2007).
78. Grone, H. J., Warnecke, E. & Olbricht, C. J. Characteristics of renal tubular atrophy in experimental renovascular hypertension: A model of kidney hibernation. Nephron 72, 243-252 (1996).
79. Warncke, J. et al. A hibernating kidney - ischemic preconditioning in a renal transplant recipient with a proximal stenosis of the iliac artery. Clin. Nephrol. 70, 168-171 (2008).
80. Baranova, O. et al. Neuron-specific inactivation of the hypoxia inducible factor 1 alpha increases brain injury in a mouse model of transient focal cerebral ischemia. J. Neurosci. 27, 6320-6332 (2007).
81. Stenzel-Poore, M. P. et al. Effect of ischaemic preconditioning on genomic response to cerebral ischaemia: Similarity to neuroprotective strategies in hibernation and hypoxia-tolerant states. Lancet 362, 1028-1037 (2003).
82. Matsumoto, M. et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J. Am. Soc. Nephrol. 14, 1825-1832 (2003).
83. Witteles, R. M. & Fowler, M. B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol. 51, 93-102 (2008).
84. van Herpen, N. A. & Schrauwen-Hinderling, V. B. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol. Behav. 94, 231-241 (2008).
85. Patel, A. et al. Early stress protein gene expression in a human model of ischemic preconditioning. Transplantation 78, 1479-1487 (2004).
86. Alchera, E. et al. Adenosine-dependent activation of hypoxia-inducible factor-1 induces late preconditioning in liver cells. Hepatology 48, 230-239 (2008).
87. Amador, A. et al. Ischemic pre-conditioning in deceased donor liver transplantation: A prospective randomized clinical trial. Am. J. Transplant. 7, 2180-2189 (2007).
88. Grenz, A. et al. Protective role of ecto-5′-nucleotidase (CD73) in renal ischemia. J. Am. Soc. Nephrol. 18, 833-845 (2007).
89. Gidday, J. M. Cerebral preconditioning and ischaemic tolerance. Nature Rev. Neurosci. 7, 437-448 (2006).
90. Sharp, F. R. et al. Hypoxic preconditioning protects against ischemic brain injury. NeuroRx 1, 26-35 (2004).
91. Jones, N. M. & Bergeron, M. Hypoxic preconditioning induces changes in HIF-1 target genes in neonatal rat brain. J. Cereb. Blood Flow Metab. 21, 1105-1114 (2001).
92. Cai, Z. et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1α. Cardiovasc. Res. 77, 463-470 (2008).
93. Dendorfer, A. et al. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals. Free Radic. Biol. Med. 38, 117-124 (2005).
94. Philipp, S. et al. Desferoxamine and ethyl-3,4-dihydroxybenzoate protect myocardium by activating NOS and generating mitochondrial ROS. Am. J. Physiol. Heart Circ. Physiol. 290, H450-H457 (2006).
95. Bergeron, M. et al. Role of hypoxia-inducible factor-1 in hypoxia-induced ischemic tolerance in neonatal rat brain. Ann. Neurol. 48, 285-296 (2000).
96. Sarco, D. P., Becker, J., Palmer, C., Sheldon, R. A. & Ferriero, D. M. The neuroprotective effect of deferoxamine in the hypoxic-ischemic immature mouse brain. Neurosci. Lett. 282, 113-116 (2000).
97. Rosenberger, C. et al. Activation of hypoxia inducible factors (HIF) ameliorates hypoxic distal tubular injury in the isolated perfused rat kidney. Nephrol. Dial. Transplant. 23, 3472-3478 (2008).
98. Otani, H. Ischemic preconditioning: From molecular mechanisms to therapeutic opportunities. Antioxid. Redox Signal. 10, 207-247 (2008).
99. Obrenovitch, T. P. Molecular physiology of preconditioning-induced brain tolerance to ischemia. Physiol. Rev. 88, 211-247 (2008).
100. Synnestvedt, K. et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993-1002 (2002).
101. Kong, T., Westerman, K. A., Faigle, M., Eltzschig, H. K. & Colgan, S. P. HIF-dependent induction of adenosine A2B receptor in hypoxia. FASEB J. 20, 2242-2250 (2006).
102. 2B adenosine receptor protects the kidney from ischemia. PLoS Med. 5, e137 (2008).
103. Hausenloy, D. J., Tsang, A., Mocanu, M. M. & Yellon, D. M. Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am. J. Physiol. Heart Circ. Physiol. 288, H971-H976 (2005).
104. Murphy, E. & Steenbergen, C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol. Rev. 88, 581-609 (2008).
105. Hausenloy, D. J., Tsang, A. & Yellon, D. M. The reperfusion injury salvage kinase pathway: A common target for both ischemic preconditioning and postconditioning. Trends Cardiovasc. Med. 15, 69-75 (2005).
106. Halestrap, A. P., Clarke, S. J. & Khaliulin, I. The role of mitochondria in protection of the heart by preconditioning. Biochim. Biophys. Acta 1767, 1007-1031 (2007).
107. 2+ overload during simulated ischemia and reperfusion: Possible mechanism of cardioprotection. Circ. Res. 89, 891-898 (2001).
108. Leonard, M. O. et al. Reoxygenation-specific activation of the antioxidant transcription factor Nrf2 mediates cytoprotective gene expression in ischemia-reperfusion injury. FASEB J. 20, 2624-2626 (2006).
109. Cai, Z. & Semenza, G. L. PTEN activity is modulated during ischemia and reperfusion: Involvement in the induction and decay of preconditioning. Circ. Res. 97, 1351-1359 (2005).
110. Mocanu, M. M. & Yellon, D. M. PTEN, the Achilles' heel of myocardial ischaemia/reperfusion injury? Br. J. Pharmacol. 150, 833-838 (2007).
111. Palacios-Callender, M., Quintero, M., Hollis, V. S., Springett, R. J. & Moncada, S. Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase. Proc. Natl Acad. Sci. USA 101, 7630-7635 (2004).
112. Quintero, M., Brennan, P. A., Thomas, G. J. & Moncada, S. Nitric oxide is a factor in the stabilization of hypoxia-inducible factor-1α in cancer: Role of free radical formation. Cancer Res. 66, 770-774 (2006).
113. Jefayri, M. K., Grace, P. A. & Mathie, R. T. Attenuation of reperfusion injury by renal ischaemic preconditioning: The role of nitric oxide. BJU Int. 85, 1007-1013 (2000).
114. Park, K. M. et al. Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J. Biol. Chem. 278, 27256-27266 (2003).
115. Guo, Y. et al. The late phase of ischemic preconditioning is abrogated by targeted disruption of the inducible NO synthase gene. Proc. Natl Acad. Sci. USA 96, 11507-11512 (1999).
116. Date, T. et al. Expression of constitutively stable hybrid hypoxia-inducible factor-1α protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury. Am. J. Physiol. Cell Physiol. 288, C314-C320 (2005).
117. Grimm, C. et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nature Med. 8, 718-724 (2002).
118. Zhu, Y., Zhang, Y., Ojwang, B. A., Brantley, M. A. Jr & Gidday, J. M. Long-term tolerance to retinal ischemia by repetitive hypoxic preconditioning: Role of HIF-1α and heme oxygenase-1. Invest. Ophthalmol. Vis. Sci. 48, 1735-1743 (2007).
119. Bernaudin, M. et al. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J. Cereb. Blood Flow Metab. 22 393-403 (2002).
120. Wick, A. et al. Neuroprotection by hypoxic preconditioning requires sequential activation of vascular endothelial growth factor receptor and Akt. J. Neurosci. 22, 6401-6407 (2002).
121. Peng, Z. et al. Up-regulated HIF-1α is involved in the hypoxic tolerance induced by hyperbaric oxygen preconditioning. Brain Res. 1212, 71-78 (2008).
122. Prass, K. et al. Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin. Stroke 34, 1981-1986 (2003).
123. Nishijima, K. et al. Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am. J. Pathol. 171, 53-67 (2007).
124. Malhotra, S., Savitz, S. I., Ocava, L. & Rosenbaum, D. M. Ischemic preconditioning is mediated by erythropoietin through PI-3 kinase signaling in an animal model of transient ischemic attack. J. Neurosci. Res. 83, 19-27 (2006).
125. Schlisio, S. et al. The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 22, 884-893 (2008).
126. Kariko, K., Weissman, D. & Welsh, F. A. Inhibition of toll-like receptor and cytokine signaling - a unifying theme in ischemic tolerance. J. Cereb. Blood Flow Metab. 24, 1288-1304 (2004).
127. Saadi, S., Wrenshall, L. E. & Platt, J. L. Regional manifestations and control of the immune system. FASEB J. 16, 849-856 (2002).
128. Schor, H., Vaday, G. G. & Lider, O. Modulation of leukocyte behavior by an inflamed extracellular matrix. Dev. Immunol. 7, 227-238 (2000).
129. Zinkernagel, A. S., Johnson, R. S. & Nizet, V. Hypoxia inducible factor (HIF) function in innate immunity and infection. J. Mol. Med. 85, 1339-1346 (2007).
130. Cramer, T. et al. HIF-1α is essential for myeloid cell-mediated inflammation. Cell 112, 645-657 (2003).
131. Kim, H. Y. et al. HIF-1α expression in response to lipopolysaccaride mediates induction of hepatic inflammatory cytokine TNFα. Exp. Cell Res. 313, 1866-1876 (2007).
132. Peyssonnaux, C. et al. Cutting edge: Essential role of hypoxia inducible factor-1α in development of lipopolysaccharide-induced sepsis. J. Immunol. 178, 7516-7519 (2007).
133. Peyssonnaux, C. et al. HIF-1α expression regulates the bactericidal capacity of phagocytes. J. Clin. Invest. 115, 1806-1815 (2005).
134. Walmsley, S. R. et al. Neutrophils from patients with heterozygous germline mutations in the von Hippel Lindau protein (pVHL) display delayed apoptosis and enhanced bacterial phagocytosis. Blood 108, 3176-3178 (2006).
135. Walmsley, S. R. et al. Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J. Exp. Med. 201 105-115 (2005).
136. Cummins, E. P. et al. Prolyl hydroxylase-1 negatively regulates IκB kinase-β, giving insight into hypoxia-induced NFκB activity. Proc. Natl Acad. Sci. USA 103, 18154-18159 (2006).
137. Rius, J. et al. NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α. Nature 453, 807-811 (2008).
138. Nishi, K. et al. LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner. Antioxid. Redox Signal. 10, 983-996 (2008).
139. Hartmann, H. et al. Hypoxia-independent activation of HIF-1 by enterobacteriaceae and their siderophores. Gastroenterology 134 756-767 (2008).
140. Taylor, C. T. & Colgan, S. P. Hypoxia and gastrointestinal disease. J. Mol. Med. 85, 1295-1300 (2007).
141. Karhausen, J. et al. Epithelial hypoxia-inducible factor-1 is protective in murine experimental colitis. J. Clin. Invest. 114 1098-1106 (2004).
142. Cummins, E. P. et al. The hydroxylase inhibitor dimethyl oxalylglycine is protective in a murine model of colitis. Gastroenterology 134, 156-165 (2008).
143. Robinson, A. et al. Mucosal protection by hypoxia. inducible factor prolyl hydroxylase inhibition. Gastroenterology 134, 145-155 (2008).
144. Greten, F. R. et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118, 285-296 (2004).
145. Thiel, M. et al. Targeted deletion of HIF-1α gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS ONE 2, e853 (2007).
146. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047-1053 (2004).
147. Hosogai, N. et al. Adipose tissue hypoxia in obesity and its impact on adipocytokine dysregulation. Diabetes 56, 901-911 (2007).
148. Ye, J., Gao, Z., Yin, J. & He, Q. Hypoxia is a potential risk factor for chronic inflammation and adiponectin reduction in adipose tissue of oblob and dietary obese mice. Am. J. Physiol. Endocrinol. Metab. 293, E1118-E1128 (2007).
149. Yun, Z., Maecker, H. L., Johnson, R. S. & Giaccia, A. J. Inhibition of PPAR2 gene expression by the HIF-1-regulated gene DEC1/Stra13: A mechanism for regulation of adipogenesis by hypoxia. Dev. Cell 2, 331-341 (2002).
150. Shimba, S., Wada, T., Hara, S. & Tezuka, M. EPAS1 promotes adipose differentiation in 3T3-L1 cells. J. Biol. Chem. 279, 40946-40953 (2004).
151. Wada, T., Shimba, S. & Tezuka, M. Transcriptional regulation of the hypoxia inducible factor-2α (HIF-2α) gene during adipose differentiation in 3T3-L1 cells. Biol. Pharm. Bull. 29, 49-54 (2006).
152. Floyd, Z. E., Kilroy, G., Wu, X. & Gimble, J. M. Effects of prolyl hydroxylase inhibitors on adipogenesis and hypoxia inducible factor 1 alpha levels under normoxic conditions. J. Cell Biochem. 101 1545-1557 (2007).
153. Irwin, R., LaPres, J. J., Kinser, S. & McCabe, L. R. Prolyl-hydroxylase inhibition and HIF activation in osteoblasts promotes an adipocytic phenotype. J. Cell Biochem. 100, 762-772 (2007).
154. McDonough, M. A. et al. Selective inhibition of factor inhibiting hypoxia-inducible factor. J. Am. Chem. Soc. 127, 7680-7681 (2005).
155. Hirsila, M. et al. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J. 19, 1308-1310 (2005).
156. McDonough, M. A. et al. Cellular oxygen sensing: Crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc. Natl Acad. Sci. USA 103, 9814-9819 (2006).
157. Schofield, C. J. & Ratcliffe, P. J. Oxygen sensing by HIF hydroxylases. Nature Rev. Mol. Cell Biol. 5, 343-354 (2004).
158. Salnikow, K. et al. Depletion of intracellular ascorbate by the carcinogenic metals nickel and cobalt results in the induction of hypoxic stress. J. Biol. Chem. 279, 40337-40344 (2004).
159. Yoon, Y. S., Cho, H., Lee, J. H. & Yoon, G. Mitochondrial dysfunction via disruption of complex II activity during iron chelation-induced senescence-like growth arrest of Chang cells. Ann. NY Acad. Sci. 1011, 123-132 (2004).
160. Needleman, P., Turk, J., Jakschik, B. A., Morrison, A. R. & Lefkowith, J. B. Arachidonic acid metabolism. Annu. Rev. Biochem. 55, 69-102 (1986).
161. Hewitson, K. S., McNeill, L. A. & Schofield, C. J. Modulating the hypoxia-inducible factor signaling pathway: Applications from cardiovascular disease to cancer. Curr. Pharm. Des. 10, 821-833 (2004).
162. Nangaku, M. et al. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler. Thromb. Vasc. Biol. 27, 2548-2554 (2007).
163. Dann, C. E. 3rd, Bruick, R. K. & Deisenhofer, J. Structure of factor-inhibiting hypoxia-inducible factor 1: An asparaginyl hydroxylase involved in the hypoxic response pathway. Proc. Natl Acad. Sci. USA 99, 15351-15356 (2002).
164. Elkins, J. M. et al. Structure of factor-inhibiting hypoxia-inducible factor (HIF) reveals mechanism of oxidative modification of HIF-1α. J. Biol. Chem. 278, 1802-1806 (2003).
165. Villar, D., Vara-Vega, A., Landazuri, M. O. & Del Peso, L. Identification of a region on hypoxia-inducible-factor prolyl 4-hydroxylases that determines their specificity for the oxygen degradation domains. Biochem. J. 408, 231-240 (2007).
166. Barth, S. et al. The peptidyl prolyl cis/trans isomerase FKBP38 determines hypoxia-inducible transcription factor prolyl-4-hydroxylase PHD2 protein stability. Mol. Cell. Biol. 27, 3758-3768 (2007).
167. Hopfer, U., Hopfer, H., Jablonski, K., Stahl, R. A. & Wolf, G. The novel WD-repeat protein Morg1 acts as a molecular scaffold for hypoxia-inducible factor prolyl hydroxylase 3 (PHD3). J. Biol. Chem. 281, 8645-8655 (2006).
168. Baek, J. H. et al. OS-9 interacts with hypoxia-inducible factor 1α and prolyl hydroxylases to promote oxygen-dependent degradation of HIF-1α. Mol. Cell 17, 503-512 (2005).
169. Ozer, A., Wu, L. C. & Bruick, R. K. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc. Natl Acad. Sci. USA 102, 7481-7486 (2005).
170. Willam, C. et al. Peptide blockade of HIFα degradation modulates cellular metabolism and angiogenesis. Proc. Natl Acad. Sci. USA 99, 10423-10428 (2002).
171. Lee, C., Kim, S. J., Jeong, D. G., Lee, S. M. & Ryu, S. E. Structure of human FIH-1 reveals a unique active site pocket and interaction sites for HIF-1 and von Hippel-Lindau. J. Biol. Chem. 278, 7558-7563 (2003).
172. -mice. Mol. Cell. Biol. 28 3386-3400 (2008).
173. Takeda, K. et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood 111, 3229-3235 (2008).
174. Takeda, K. et al. Placental but not heart defects are associated with elevated hypoxia-inducible factor a levels in mice lacking prolyl hydroxylase domain protein 2. Mol. Cell. Biol. 26, 8336-8346 (2006).
175. Percy, M. J. et al. A gain-of-function mutation in the HIF2A gene in familial erythrocytosis. N. Engl. J. Med. 358, 162-168 (2008).
176. Percy, M. J. et al. A family with erythrocytosis establishes a role for prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc. Natl Acad. Sci. USA 103, 654-659 (2006).
177. Ang, S. O. et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nature Genet. 32, 614-621 (2002).
178. Gordeuk, V. R. et al. Congenital disorder of oxygen sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 103 3924-3932 (2004).
179. Smith, T. G., Robbins, P. A. & Ratcliffe, P. J. The human side of hypoxia-inducible factor. Br. J. Haematol. 141, 325-334 (2008).
180. Semenza, G. L. & Prabhakar, N. R. HIF-1-dependent respiratory, cardiovascular, and redox responses to chronic intermittent hypoxia. Antioxid. Redox Signal. 9, 1391-1396 (2007).
181. Baader, E., Tschank, G., Baringhaus, K. H., Burghard, H. & Gunzler, V. Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues. Biochem. J. 300, 525-530 (1994).
182. Ivan, M. et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc. Natl Acad. Sci. USA 99, 13459-13464 (2002).
183. Mole, D. R. et al. 2-oxoglutarate analogue inhibitors of HIF prolyl hydroxylase. Bioorg. Med. Chem. Lett. 13, 2677-2680 (2003).
184. Hamrick, S. E. et al. A role for hypoxia-inducible factor-1α in desferoxamine neuroprotection. Neurosci. Lett. 379, 96-100 (2005).
185. Majamaa, K., Gunzler, V., Hanauske-Abel, H. M., Myllyla, R. & Kivirikko, K. I. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J. Biol. Chem. 261, 7819-7823 (1986).
186. Majamaa, K., Sasaki, T. & Uitto, J. Inhibition of prolyl hydroxylation during collagen biosynthesis in human skin fibroblast cultures by ethyl 3,4-dihydroxy benzoate. J. Invest. Dermatol. 89, 405-409 (1987).
187. Sasaki, T., Majamaa, K. & Uitto, J. Reduction of collagen production in keloid fibroblast cultures by ethyl-3,4-dihydroxybenzoate. Inhibition of prolyl hydroxylase activity as a mechanism of action. J. Biol. Chem. 262, 9397-9403 (1987).
188. Warnecke, C. et al. Activation of the hypoxia-inducible
189. Nwogu, J. I. et al. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104, 2216-2221 (2001).
190. Linden, T. et al. The antimycotic ciclopirox olamine induces HIF-1alpha stability, VEGF expression, and angiogenesis. FASEB J. 17, 761-763 (2003).
191. Ju, H., Hao, J., Zhao, S. & Dixon, I. M. Antiproliferative and antifibrotic effects of mimosine on adult cardiac fibroblasts. Biochim. Biophys. Acta 1448, 51-60 (1998).
192. McCaffrey, T. A. et al. Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries. J. Clin. Invest. 95, 446-455 (1995).
193. Schlemminger, I. et al. Analogues of dealanylalahopcin are inhibitors of human HIF prolyl hydroxylases. Bioorg. Med. Chem. Lett. 13, 1451-1454 (2003).
194. Warshakoon, N. C. et al. Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg. Med. Chem. Lett. 16, 5517-5522 (2006).
195. Warshakoon, N. C. et al. Design and synthesis of a series of novel pyrazolopyridines as HIF-1α prolyl hydroxylase inhibitors. Bioorg. Med. Chem. Lett. 16, 5687-5690 (2006).